---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-26-000019"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2026-05-13T20:07:44+00:00"
generated_at: "2026-05-13T20:10:52.309778+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA

## Summary
- Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.
- Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).
- Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.
- FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.
- Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial.

## SEC filing metadata
- accession: 0001055726-26-000019
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2026-05-13T20:07:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/0001055726-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-26-000019
- JSON: https://secwatch.observer/filing/0001055726-26-000019.json
- Plain text: https://secwatch.observer/filing/0001055726-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.